title: Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence.
abstract: OBJECTIVE
  Hypercalcemia is a frequent finding in cancer patients and can be observed in any type of cancer. The physician in charge of cancer patients often ignores non-malignant causes of hypercalcemia. Our objective was to review the causes of hypercalcemia in a large series of cancer patients.
  
  
  METHODS
  We have retrospectively studied in a Cancer Centre all consecutive hypercalcemic (Ca> 10.5 mg/dl) patients over an 8-year period. Of 699 evaluated patients, 642 were analyzed after exclusion of patients whose hypercalcemia resolved after rehydration or who had a normal Ca level after correction for protein concentrations. Clinical information was gathered on the type of cancer, its histology, whether the disease was active or in complete remission, and on the presence of bone metastases. Biochemical data included serum Ca, P(i), proteins in all patients, PTH in most patients, and PTHrP, 25OH-Vitamin D, 1,25(OH)(2)-Vitamin D, TSH, and T4 in selected cases.
  
  
  RESULTS
  By order of decreasing frequency, the main causes of hypercalcemia were cancer (69.0 %), primary hyperparathyroidism (24.6 %), hyperthyroidism (2.2 %), milk alkali syndrome (0.9 %), and sarcoidosis (0.45 %). In cancer-related causes, bone metastases accounted for 53.0 % of the cases, humoral hypercalcemia of malignancy (HHM) for 35.3 % while there were 11.7 % of cases apparently due to both HHM and bone metastases. Hypercalcemia was not due to cancer in 97 % (84/87) of the patients who were in complete remission. Even in patients with active neoplastic disease, the number of patients whose hypercalcemia was not due to cancer remained clinically relevant (115/555 = 20.5 %). In the 158 patients with primary hyperparathyroidism, 92 patients were in complete remission and 66 patients had active neoplastic disease.
  
  
  CONCLUSIONS
  In this large series of hypercalcemia in cancer patients, the cause was not due to cancer in almost one third of the cases. Most patients considered to be in complete remission had hypercalcemia due to a benign condition. In that perspective, serum PTH determination is essential in the approach of hypercalcemic cancer patients since primary hyperparathyroidism is by far the first non-malignant cause of hypercalcemia.
authors.affiliation: Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: M S
authors.initials: MS
authors.lastname: Soyfoo
authors.forename: K
authors.initials: K
authors.lastname: Brenner
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: J J
authors.initials: JJ
authors.lastname: Body
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002173:Cancer Care Facilities; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000453:epidemiology / Q000209:etiology*; D049950:Hyperparathyroidism, Primary / Q000150:complications* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000473:pathology*; D010281:Parathyroid Hormone / Q000097:blood*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D010281:Parathyroid Hormone